Cited by 140Lipid metabolism and disordersDiabetes, Cardiovascular Risks, and LipoproteinsLipoproteins and Cardiovascular Health

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease

Open access

Olivieri, Oliviero, Bassi, Antonella, Stranieri, Chiara, Trabetti, Elisabetta, Martinelli, Nicola, Pizzolo, Francesca, Girelli, Domenico, Friso, Simonetta, Pignatti, Pier Franco, Corrocher, Roberto·2003·Journal of Lipid Research

DOI 10.1194/jlr.m300253-jlr200

Open this paper in CoChat — free account

Abstract

Apolipoprotein C-III (apoC-III) is a marker of triglyceride (TG)-rich lipoproteins, which are often increased in metabolic syndrome (MS). The T-455C polymorphism in the insulin-responsive element of the APOC3 gene influences TG and apoC-III levels. To evaluate the contribution of apoC-III levels and T-455C polymorphisms in the coronary artery disease (CAD) risk of MS patients, we studied 873 patients, 549 with CAD and 251 with normal coronary arteries. Patients were classified also as having or not having MS (MS, n = 270; MS-free, n = 603). Lipids, insulin, apolipoprotein levels, and APOC3 T-455C genotypes were evaluated. ApoC-III levels were significantly increased in MS patients, and the probability of having MS was correlated with increasing quartiles of apoC-III levels. MS patients with CAD had significantly higher apoC-III levels than did CAD-free MS patients. The carriership for the -455C variant multiplied the probability of CAD in MS in an allele-specific way and was associated with increased apoC-III and TG levels. Obesity was less frequent in MS carriers of the -455C allele than in MS noncarriers (21.6% vs. 34.8%, P < 0.05). In conclusion, apoC-III-rich lipoprotein metabolism and the APOC3 polymorphism have relevant impacts on the CAD risk of MS patents.

Integrity signals

Registry

Crossref · 10.1194/jlr.m300253-jlr200

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Prevalence of the Metabolic Syndrome Among US Adults: Findings From the Third National Health and Nutrition Examination Survey
Ford, E. S., Giles, W. H., & Dietz, W. H. (2002) · JAMA · doi:10.1001/jama.287.3.356 · Cited by 6,698
Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.-R., & Groop, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.683 · Cited by 4,760
Insulin resistance and cardiovascular disease
Ginsberg, H. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10762 · Cited by 1,372
An Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing
Pennacchio, L. A., Olivier, M., Hubacek, J. A., Cohen, J. C., Cox, D. R., Fruchart, J.-C., Krauss, R. M., & Rubin, E. M. (2001) · Science · doi:10.1126/science.1064852 · Cited by 921
Role of apoCs in lipoprotein metabolism: functional differences between apoC1, apoC2, and apoC3
Jong, M. C., Hofker, M. H., & Havekes, L. M. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.3.472 · Cited by 539
VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial
Sacks, F. M., Alaupovic, P., Moye, L. A., Cole, T. G., Sussex, B., Stampfer, M. J., Pfeffer, M. A., & Braunwald, E. (2000) · Circulation · doi:10.1161/01.cir.102.16.1886 · Cited by 490
Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI: evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo
Ginsberg, H. N., Le, N. A., Goldberg, I. J., Gibson, J. C., Rubinstein, A., Wang-Iverson, P., Norum, R., & Brown, W. V. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112713 · Cited by 424 · cited 1×
“ApoC-III inhibits the hydrolysis of TG-rich particles by the lipoprotein lipase and their hepatic uptake mediated by apoE (9, 10 ).”
Background

Show all 36 references

Sorted by citations

Items 101–140 of 140

Ethnicity differences in plasma apoC-III levels between African American and Caucasian youths
Lee, J., Hong, H.-R., & Kang, H. (2011) · World Journal of Pediatrics · doi:10.1007/s12519-011-0266-8 · Cited by 4
APOA5 -1131T>C and APOC3 -455T>C polymorphisms are associated with an increased risk of coronary heart disease
Sun, Y., Zhou, R., & Chen, D. M. (2015) · Genetics and Molecular Research · doi:10.4238/2015.december.23.9 · Cited by 4
Triglyceride Level Affecting Shared Susceptibility Genetic Variants in Type 2 Diabetes Mellitus
Sümegi, K. (2013) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.s13-007 · Cited by 3
Triglyceride-independent associations between circulating levels of apolipoprotein C-III and biomarkers of inflammation
Llop, D., Rehues, P., Paredes, S., Guardiola, M., Girona, J., Rosales, R., Esteban, Y., Masana, L., Ibarretxe, D., Vallvé, J.-C., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02553-z · Cited by 2
Elevated levels of apolipoprotein C3 impair platelet function and reduce thrombosis
Schrottmaier, W. C., Kral-Pointner, J. B., Mußbacher, M., Salzmann, M., Hochreiter, B., Pirabe, A., Reiter, T., Badrnya, S., Schmid, J. A., Volf, I., et al. (2026) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2026.01.004 · Cited by 2
Multiple genetic polymorphisms are associated with the risk of metabolic syndrome, fatty liver, and airflow limitation: A Taiwan Biobank study
Shen, H., Pan, M., Huang, C.-J., Yeh, H., Yang, H., Lin, Y., Huang, C., Lee, K., Yang, Y., & Hou, M. (2024) · Gene · doi:10.1016/j.gene.2024.148660 · Cited by 2
Radioprotectors and Mitigators: Current Status
Yazlovitskaya, E. M. (2013) · Journal of Bioequivalence & Bioavailability · doi:10.4172/jbb.10000e26 · Cited by 2
Hepatocyte nuclear factor 4a and glucocorticoid receptor coordinately regulate lipid metabolism in mice fed a high-fat-high-sugar dietPreprint
Lü, H., Lei, X., Guo, S., Winkler, R., John, S., Kumar, D., Li, W., & Alnouti, Y. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.06.427306 · Cited by 2
Role of APOC3 3238C/G polymorphism in HIV-associated neurocognitive disorder
Singh, H., Dhotre, K., Shyamveer, Namdev, G., Mahajan, S. D., Parvez, M. K., & Al-Dosari, M. S. (2023) · Microbial Pathogenesis · doi:10.1016/j.micpath.2023.106107 · Cited by 1
Association of Apolipoprotein C-III Gene Polymorphisms (rs2854116 and rs2854117) with Susceptibility to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a Turkish Population
Karaagac, D., Morkuzu, S., Şenkal, N., Bilgin, E., Oyacı, Y., Tükek, T., Pehlıvan, S., & Medetalibeyoglu, A. (2025) · Medicina · doi:10.3390/medicina61081479 · Cited by 2
Residual Risk Reduction Initiative: výzva ke snížení reziduálního vaskulárního rizika u pacientů s dyslipidemií
Fruchart, J., Sacks, F. M., Hermans, M. P., Assmann, G., Brown, W. V., Češka, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2010) · Cor et Vasa · doi:10.33678/cor.2010.056 · Cited by 1
Apolipoprotein A5 and apolipoprotein C3 single nucleotide polymorphisms are correlated with an increased risk of coronary heart disease: a case–control and meta-analysis study
Yang, G., Lei, M.-M., Yu, C.-L., Liu, X.-X., An, Z., & Song, C.-L. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0110-6 · Cited by 1
Beyond Cholesterol: Statin Benefits in Alzheimer's Disease
Soares, H. D., & Sparks, D. L. (2007) · Springer eBooks · doi:10.1007/7355_2007_013 · Cited by 1
Synergic effects of the ApoC3 and ApoA4 polymorphisms on the risk of hypertension
Kang, S. H., Kim, Y. R., & Hong, S.-H. (2017) · Genes & Genomics · doi:10.1007/s13258-017-0606-8 · Cited by 1
Assessment and Treatment of Cardiovascular Disease in Obese Children
Blackett, P. R., Alaupovic, P., Short, K. R., & Copeland, K. C. (2011) · Humana Press eBooks · doi:10.1007/978-1-60327-256-8_5 · Cited by 1
Nature vs nurture: genetic susceptibility and weight loss in hepatic steatosis
Huang, K. (2010) · Clinical Genetics · doi:10.1111/j.1399-0004.2010.01519_3.x · Cited by 1
Interaction between Diet and Genes on Longevity
Puca, A. A., Anselmi, C. V., & Perls, T. T. (2011) · Wiley eBooks · doi:10.1002/9781444318456.ch51
A cross-sectional analysis of the RISC Study
Baldi, S., Bonnet, F., Laville, M., Morgantini, C., Monti, L. D., Højlund, K., Ferrannini, E., & Natali, A. (2013) · Cited by 1
Obesity and metabolic syndrome among
Ali, F. T., Ismail, M. A., El-Azeem, E. M. A., Abdulla, A. M., & Seoudi, D. M. (2014)
Clustering of Cardiometabolic Risk Factors, Liver Enzymes and PNPLA3 Polymorphism With Special Reference To Children
Viitasalo, A. (2015) · UEF eRepo (University of Eastern Finland)
Allele Frequency of C-482T Polymorphism in Apolipoprotein CIII Gene in a Tehranian Population: Tehran Lipid and Glucose Study
Shojaee, S., DANESHPOUR, M. S., Halalkhor, S., Azizi, F., & Hedayati, M. (2010) · Majallah-i ghudad-i darūn/rīz va mitābulīsm-i Īrān./Majallah-i ghudad-i darūn/rīz va mitābulīsm-i Īrān.
Study diabetes-related endothelial cell dysfunction in a hemodynamic microfluidic system
Liu, X. (2016) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/65987
Triglycerides and Risk for Atherosclerotic Disease
Luc, G., Duriez, P., & Fruchart, J. (2013) · CRC Press eBooks · doi:10.3109/9781420019667-15
Frequencies of the T-455C and C-482T apoCIII gene polymorphisms in different South African population groups and their relationship to fasting serum triglyceride levels
Naran, N. H., Raal, F. J., & Crowther, N. J. (2017) · SA Heart · doi:10.24170/6-3-1985
The effect of longer-term plant sterol and stanol consumption on apolipoprotein CII and apolipoprotein CIII concentrations in humans
Lemmens, C. (2016) · MaRBLe · doi:10.26481/marble.2014.v2.310
Association between apolipoprotein C3 gene promoter polymorphisms and fasting triglyceride level: A meta-analysis
Cheng, S., Pang, B., Gu, C., Sun, S., An, C., Zhang, Z., Li, J., & Liu, G.-J. (2017) · Frontiers in Laboratory Medicine · doi:10.1016/j.flm.2017.10.002
Triglycerides and Risk for Atherosclerotic Disease
Luc, G., Duriez, P., & Fruchart, J. (2006) · Fundamental and clinical cardiology · doi:10.3109/9781420019667.009
FEATURES OF CORONARY ARTERIES LESION AT UNSTABLE ANGINA PATIENTS DEPENDING ON DISTRIBUTION OF APO С-III GENE POLYMORPHISM AND TYPE OF DISLIPIDEMIA
Eshpulatov, A. S., Hoshimov, S. U., Kan, L. E., Ахмедова, Ш. С., Аминов, С. А., Хусаиновна, Т. Р., Shek, A. B., & Kurbanov, R. D. (2014) · Eurasian heart journal · doi:10.38109/2225-1685-2014-3-30-36
Additional file 5 of Crosstalk of hepatocyte nuclear factor 4a and glucocorticoid receptor in the regulation of lipid metabolism in mice fed a high-fat-high-sugar diet
Lü, H., Lei, X., Winkler, R., John, S., Kumar, D., Li, W., & Alnouti, Y. (2022) · Figshare · doi:10.6084/m9.figshare.19881329
Role of APOC3 3238C/G, APOB 12669G/A and SCARB1 1050C/T polymorphisms, their expression in patients of HIV-associated lipodystrophy
Singh, H., Shyamveer, Jori, C., Mahajan, S. D., Aalinkeel, R., Kaliyappan, K., Bhattacharya, M., Parvez, M. K., & Al-Dosari, M. S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30519
Increased circulating apolipoprotein Cs are implicated in the association between elevated serum retinol and retinol-binding protein 4 and adverse progression of metabolic syndrome in adults: A prospective study
Chen, D., Xie, K., Gao, C., Yang, Y., Xu, Y., Xi, Y., Xi, Y., Zheng, J.-S., & Chen, Y. (2025) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2025.109892
Characterization of metabolically healthy and unhealthy obesity through circulating proteins and metabolitesPreprint
Pontali, G., Weichenberger, C. X., Rainer, J., Hantikainen, E. M., Graeve, M. D., Mattivi, F., Kob, M., Ralser, M., Pramstaller, P. P., & Domingues, F. S. (2025) · medRxiv · doi:10.1101/2025.03.10.25323679
Antecedents, characterisation and validity of cardiovascular disease biomarkers amongst South Asians in the UK
Chackathayil, J. (2013) · University of Birmingham Institutional Research Archive (University of Birmingham)
Additional file 3 of Crosstalk of hepatocyte nuclear factor 4a and glucocorticoid receptor in the regulation of lipid metabolism in mice fed a high-fat-high-sugar diet
Lu, H., Lei, X., Winkler, R., John, S., Kumar, D., Li, W., & Alnouti, Y. (2022) · Figshare · doi:10.6084/m9.figshare.19881323
Additional file 4 of Crosstalk of hepatocyte nuclear factor 4a and glucocorticoid receptor in the regulation of lipid metabolism in mice fed a high-fat-high-sugar diet
Lu, H., Lei, X., Winkler, R., John, S., Kumar, D., Li, W., & Alnouti, Y. (2022) · Figshare · doi:10.6084/m9.figshare.19881326
Additional file 7 of Crosstalk of hepatocyte nuclear factor 4a and glucocorticoid receptor in the regulation of lipid metabolism in mice fed a high-fat-high-sugar diet
Lu, H., Lei, X., Winkler, R., John, S., Kumar, D., Li, W., & Alnouti, Y. (2022) · Figshare · doi:10.6084/m9.figshare.19881335
Additional file 1 of Crosstalk of hepatocyte nuclear factor 4a and glucocorticoid receptor in the regulation of lipid metabolism in mice fed a high-fat-high-sugar diet
Lu, H., Lei, X., Winkler, R., John, S., Kumar, D., Li, W., & Alnouti, Y. (2022) · Figshare · doi:10.6084/m9.figshare.19881317
Additional file 6 of Crosstalk of hepatocyte nuclear factor 4a and glucocorticoid receptor in the regulation of lipid metabolism in mice fed a high-fat-high-sugar diet
Lu, H., Lei, X., Winkler, R., John, S., Kumar, D., Li, W., & Alnouti, Y. (2022) · Figshare · doi:10.6084/m9.figshare.19881332
Additional file 2 of Crosstalk of hepatocyte nuclear factor 4a and glucocorticoid receptor in the regulation of lipid metabolism in mice fed a high-fat-high-sugar diet
Lu, H., Lei, X., Winkler, R., John, S., Kumar, D., Li, W., & Alnouti, Y. (2022) · Figshare · doi:10.6084/m9.figshare.19881320
Characterization of metabolically healthy and unhealthy obesity by circulating omics
Pontali, G., Weichenberger, C. X., Rainer, J., Hantikainen, E. M., Graeve, M. D., Mattivi, F., Kob, M., Ralser, M., Pramstaller, P. P., & Domingues, F. S. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104998

Authors: Olivieri, O., Bassi, A., Stranieri, C., Trabetti, E., Martinelli, N., Pizzolo, F., Girelli, D., Friso, S., Pignatti, P. F., & Corrocher, R.
Affiliations: University of Verona (IT)
Corresponding author: Olivieri, Oliviero
ORCID: Olivieri, Oliviero
Bassi, Antonella
Stranieri, Chiara
Martinelli, Nicola
Pizzolo, Francesca
Girelli, Domenico
Friso, Simonetta
Venue: Journal of Lipid Research
Publisher: Elsevier BV
Published: 2003-12
Volume: 44
Issue: 12
Pages: 2374-2381
ISSN: 0022-2275 (ISSN-L)
DOI: 10.1194/jlr.m300253-jlr200
OpenAlex: W2125644926
Cited by: 139
References: 36
Citations by year: 2026: 2 · 2025: 5 · 2024: 2 · 2023: 3 · 2022: 10 · 2021: 2 · 2020: 1 · 2018: 3 · 2017: 6 · 2016: 6 · 2015: 9 · 2014: 6 · 2013: 11 · 2012: 2
FWCI: 5.94
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
creativecommons.org/licenses/by/4.0/ (vor, 6114 d)
Locations: Journal of Lipid Research (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Keywords: apolipoprotein C-III, metabolic syndrome, coronary artery disease, triglyceride-rich lipoproteins, triglycerides, genetic susceptibility, obesity
MeSH terms: Adult, Alleles, Apolipoproteins C, Coronary Artery Disease, Data Interpretation, Statistical, Female, Genotype, Humans, Lipids, Male, Middle Aged, Polymorphism, Genetic, Substrate Specificity, Biomarkers, Odds Ratio, Genetic Predisposition to Disease, Metabolic Syndrome, Apolipoprotein C-III

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks